Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772504 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL1379540 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL1339426 | 0.87 | PTGER4 (0.47) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL1382532 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL1382531 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3567845 | 0.84 | KMT2A (0.38) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3567848 | 0.84 | KMT2A (0.38) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3576867 | 0.83 | ALDH1A1 (0.35) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3576869 | 0.83 | ALDH1A1 (0.35) | ALDH1A1HPGDKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3573716 | 0.81 | KDM4E (0.42) | ALDH1A1HPGDKMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809830-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | claimed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | claimed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | claimed |
| US-7812165-B2 | 6-substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | PNPO, CYP2D6, DPYD | ALDH1A1 628/4885HPGD 29/4885KMT2A 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.